These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 21104168)

  • 1. The place for eribulin in the treatment of metastatic breast cancer.
    Gradishar WJ
    Curr Oncol Rep; 2011 Feb; 13(1):11-6. PubMed ID: 21104168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.
    Cortes J; Lorca R
    Future Oncol; 2011 Mar; 7(3):355-64. PubMed ID: 21375468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
    Aseyev O; Ribeiro JM; Cardoso F
    Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
    Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
    Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical efficacy and safety assessment of eribulin monotherapy in patients with metastatic breast cancer - a single- institute experience].
    Hattori M; Fujita T; Sawaki M; Kondo N; Horio A; Ushio A; Gondo N; Idota A; Ichikawa M; Iwata H
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):737-41. PubMed ID: 23863649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.
    Ortega V; Antón A; Garau I; Afonso N; Calvo L; Fernández Y; Martínez-García M; Blanco E; Zamora P; García M; Illarramendi JJ; Rodríguez Sánchez CA; Sampayo M; Aguirre E; Pérez-García JM; Cortés J; Llombart-Cussac A
    Clin Breast Cancer; 2019 Apr; 19(2):105-112. PubMed ID: 30679100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
    Cortes J; Montero AJ; Glück S
    Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eribulin mesylate (Halaven) for breast cancer.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin mesylate in breast cancer.
    Verdaguer H; Morilla I; Urruticoechea A
    Womens Health (Lond); 2013 Nov; 9(6):517-26. PubMed ID: 24161305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
    O'Sullivan Coyne G; Walsh J; Kelly CM
    Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of eribulin for the treatment of metastatic breast cancer.
    Perez-Garcia JM; Cortes J
    Expert Opin Drug Saf; 2019 May; 18(5):347-355. PubMed ID: 31107111
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Heavily Pre-treated Metastatic Breast Cancer with Eribulin: First local experience in Sabah.
    Lee DW; Teoh DC; Chong FL
    Med J Malaysia; 2016 Dec; 71(6):348-350. PubMed ID: 28087961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin in heavily pretreated metastatic breast cancer: A tertiary care center experience from India.
    Bajpai J; Ramaswamy A; Gupta S; Ghosh J; Gulia S
    Indian J Cancer; 2016; 53(3):460-463. PubMed ID: 28244486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].
    Matsuzaki H; Tohnosu N; Yoshiwara C; Maruyama T; Tanaka H; Natsume T; Miyazaki A; Sato Y; Ohta T; Yamamoto Y; Aikawa M; Ohtsuka R; Yanagihara A; Iwata K; Shiratori T; Miyazawa Y
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):455-9. PubMed ID: 24743360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.